REGENXBIO Inc. (RGNX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 200M 400M 600M Q3 '21: 93.1M Q4 '21: 470.3M Q1 '22: 473.7M Q2 '22: 484.3M Q3 '22: 480M Q4 '22: 112.7M Q1 '23: 109.6M Q2 '23: 97M Q3 '23: 99.4M Q4 '23: 90.2M Q1 '24: 86.7M Q2 '24: 89M Q3 '24: 84.3M Q4 '24: 83.3M Q1 '25: 156.7M Q2 '25: 155.8M Q3 '25: 161.3M Q4 '25: 170.4M Q1 '26: 87.8M Q2 '26: 174.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 150M 300M 450M Q1 '20: 40.4M Q2 '20: 46.3M Q3 '20: 115.6M Q4 '20: 118.9M Q1 '21: 118.7M Q2 '21: 119M Q3 '21: 54.1M Q4 '21: 418.5M Q1 '22: 411M Q2 '22: 418.5M Q3 '22: 415.2M Q4 '22: 58.2M Q1 '23: 66.7M Q2 '23: 57.5M Q3 '23: 60.6M Q4 '23: 53M Q1 '24: 49.3M Q2 '24: 50.6M Q3 '24: 45.8M Q4 '24: 49.8M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '21: -207.3M Q4 '21: 160M Q1 '22: 132.5M Q2 '22: 122.2M Q3 '22: 108.5M Q4 '22: -262.9M Q1 '23: -257.5M Q2 '23: -268.1M Q3 '23: -262M Q4 '23: -268.1M Q1 '24: -265.8M Q2 '24: -248.8M Q3 '24: -245.9M Q4 '24: -233.3M Q1 '25: -157.4M Q2 '25: -164.6M Q3 '25: -154.9M Q4 '25: -161.2M Q1 '26: -256.7M Q2 '26: -164.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '20: -91.5M Q4 '20: -111.2M Q1 '21: -121.4M Q2 '21: -145.2M Q3 '21: -212.4M Q4 '22: -280.3M Q1 '23: -270.3M Q2 '23: -274.2M Q3 '23: -260.5M Q4 '23: -263.5M Q1 '24: -260.1M Q2 '24: -241.1M Q3 '24: -238.8M Q4 '24: -227.1M Q1 '25: -157.7M Q2 '25: -175.6M Q3 '25: -177.9M Q4 '25: -193.9M Q1 '26: -290M Q2 '26: -196.4M Q4 '20 Q3 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 25M 50M 75M Q1 '20: 11.6M Q2 '20: 14.4M Q3 '20: 29.2M Q4 '20: 35.7M Q1 '21: 37.2M Q2 '21: 42.3M Q3 '21: 39M Q4 '21: 51.8M Q1 '22: 62.7M Q2 '22: 65.8M Q3 '22: 64.8M Q4 '22: 54.5M Q1 '23: 42.9M Q2 '23: 39.5M Q3 '23: 38.8M Q4 '23: 37.2M Q1 '24: 37.4M Q2 '24: 38.5M Q3 '24: 38.5M Q4 '24: 33.6M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: -83.2M Q4 '21: 218.9M Q1 '22: 207M Q2 '22: 181.3M Q3 '22: 173.4M Q4 '22: -207.5M Q1 '23: -232.5M Q2 '23: -218.1M Q3 '23: -217M Q4 '23: -218.4M Q1 '24: -192.9M Q2 '24: -191.1M Q3 '24: -182.3M Q4 '24: -173.1M Q1 '25: -84M Q2 '25: -87.9M Q3 '25: -103.3M Q4 '25: -124M Q1 '26: -233.8M Q2 '26: -246.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q3 '21: -165.6M Q4 '21: 134.7M Q1 '22: 142.9M Q2 '22: 127.8M Q3 '22: 133.5M Q4 '22: -238.2M Q1 '23: -257.1M Q2 '23: -236M Q3 '23: -231.3M Q4 '23: -228.4M Q1 '24: -198.6M Q2 '24: -194.7M Q3 '24: -184.7M Q4 '24: -175.6M Q1 '25: -86.9M Q2 '25: -90.7M Q3 '25: -106.3M Q4 '25: -126.4M Q1 '26: -236.4M Q2 '26: -249.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '19: 36.4M Q2 '19: 36.7M Q3 '19: 36.8M Q3 '20: 38.9M Q2 '21: 42.5K Q3 '21: 42.6K Q1 '22: 42.9K Q2 '22: 43.1K Q3 '22: 43.3K Q1 '23: 43.5M Q2 '23: 43.5M Q3 '23: 43.9M Q1 '24: 45.7M Q2 '24: 50.6M Q3 '24: 50.8M Q1 '25: 51.4M Q2 '25: 51.5M Q3 '25: 51.7M Q1 '26: 52.4M Q2 '26: 53M Q2 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q2 '19: -1.38 Q3 '19: -1.76 Q4 '19: -2.59 Q1 '20: -2.78 Q2 '20: -3.65 Q3 '20: -2.48 Q4 '20: -3.00 Q1 '21: -3.12 Q3 '23: -5.99 Q4 '23: -6.02 Q1 '24: -5.87 Q2 '24: -5.26 Q3 '24: -5.02 Q4 '24: -4.60 Q1 '25: -3.10 Q2 '25: -3.43 Q3 '25: -3.46 Q4 '25: -3.76 Q1 '26: -5.60 Q2 '26: -3.79 Q3 '19 Q2 '20 Q1 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.